Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $262.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price increased by Wells Fargo & Company from $260.00 to $262.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 90.96% from the stock’s previous close.

Several other brokerages have also commented on ASND. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $116.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, April 22nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average target price of $173.88.

Ascendis Pharma A/S Stock Down 2.8 %

Shares of NASDAQ ASND traded down $3.90 during mid-day trading on Friday, reaching $137.20. 511,411 shares of the company were exchanged, compared to its average volume of 365,955. The firm has a 50-day moving average of $147.11 and a 200 day moving average of $127.28. Ascendis Pharma A/S has a 1 year low of $83.75 and a 1 year high of $161.00. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of -14.83 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The firm had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 91 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. PNC Financial Services Group Inc. raised its holdings in Ascendis Pharma A/S by 1.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after acquiring an additional 159 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Ascendis Pharma A/S by 1.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company’s stock valued at $1,762,000 after purchasing an additional 186 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.